Journal of VitreoRetinal Diseases最新文献_第6页

Risk Factors for Recurrent Vitreous Hemorrhage After 25-Gauge Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy. 增殖性糖尿病视网膜病变患者玻璃体切除术后玻璃体出血复发的危险因素。

IF 0.8

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251351545

Jyotsna Bitra, Haarisudhan Sureshkumar, Abhijith V Eathara, Reem Alahmadi, Michael J Heiferman

{"title":"Risk Factors for Recurrent Vitreous Hemorrhage After 25-Gauge Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy.","authors":"Jyotsna Bitra, Haarisudhan Sureshkumar, Abhijith V Eathara, Reem Alahmadi, Michael J Heiferman","doi":"10.1177/24741264251351545","DOIUrl":"10.1177/24741264251351545","url":null,"abstract":"Purpose: To report the incidence of and risk factors associated with recurrent vitreous hemorrhage (VH) in eyes that had 25-gauge pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). Methods: This study included 220 eyes of 185 patients who were 21 years old or older and who had PPV for PDR and a minimum postoperative follow-up of 3 months. For patients who had bilateral PPV, data were gathered from both eyes. If surgery was performed in only 1 eye, data were collected from that eye alone. Results: The incidence of recurrent VH was 34.5% (76 eyes). The VH was categorized as early in 46 eyes (60.5%), delayed in 8 eyes (10.5%), or late in 22 eyes (28.9%). Sixty-eight eyes (89.5%) had mild/moderate recurrent VH and 8 (10.5%) had severe recurrent VH. The mean preoperative fasting blood glucose level was 147.7 mg/dL in eyes without recurrent VH and 176.7 mg/dL in eyes with recurrent VH (P = .020). Younger age (P = .027) and higher diastolic blood pressure at the time of surgery (P = .005) also significantly affected recurrent VH. Conclusions: Younger age, preoperative fasting blood glucose levels, and diastolic blood pressure were significantly associated with recurrent VH after PPV in patients with PDR.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251351545"},"PeriodicalIF":0.8,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Novel Case of Optic Disc Edema Associated With VEXAS Syndrome. 视盘水肿合并VEXAS综合征一例新病例。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251351661

Mary A Gao, Tianyu Liu, Sandeep Randhawa

引用次数: 0

Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists. 重新包装玻璃体内贝伐单抗的供应链波动：美国视网膜专家协会的一项调查。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251352889

Hasenin Al-Khersan, Miguel Busquets, Ghassan Ghorayeb, Dan Gong, Anton Kolomeyer, Ella H Leung, Philip Niles, Nimesh A Patel, Ankoor R Shah, Charles C Wykoff, Jill Blim, Michael Jumper, Michael M Lai

{"title":"Supply Chain Volatility of Repackaged Intravitreal Bevacizumab: A Survey of the American Society of Retina Specialists.","authors":"Hasenin Al-Khersan, Miguel Busquets, Ghassan Ghorayeb, Dan Gong, Anton Kolomeyer, Ella H Leung, Philip Niles, Nimesh A Patel, Ankoor R Shah, Charles C Wykoff, Jill Blim, Michael Jumper, Michael M Lai","doi":"10.1177/24741264251352889","DOIUrl":"10.1177/24741264251352889","url":null,"abstract":"Purpose: To characterize retina specialists' perceptions of the intravitreal (IVT) bevacizumab supply chain after the manufacturer, Pine Pharmaceuticals, announced they would no longer produce the formulation. Methods: A 22-question survey was created to assess retina physicians' use of IVT bevacizumab, perceptions of the supply chain, and how the decision will affect patient care. The survey was electronically distributed to all members of the American Society of Retina Specialists. Results: The survey was completed by 287 retina specialists. In the 3 months before the survey, 194 (67.6%) physicians reported receiving IVT bevacizumab from Pine Pharmaceuticals. Approximately 85% of physicians were either very concerned (158 [55.4%]) or concerned (85 [29.8%]) about their access to the medication in the next 3 months. Most physicians anticipated needing to delay or change patient appointments (142 [50.4%]) or change patient treatment plans (179 [63.9%]) because of shortages of IVT bevacizumab. Respondents overwhelmingly believed that patients with step-therapy requirements were most likely to be affected by appointment delays (119 [83.8%]) and changes in treatment plans (140 [78.2%]). Conclusions: The majority of retina specialists surveyed expect the decision to halt production of IVT bevacizumab will significantly disrupt access to the medication and adversely affect patient care. Most physicians predict delays and changes in treatment, particularly for patients with IVT bevacizumab step-therapy requirements. Therefore, to minimize negative effects on patient care, we recommend that carriers suspend step-therapy requirements, especially given that the disruption to the supply chain is likely to be longstanding.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251352889"},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of and Surgical Technique for Treatment With High-Dose Aflibercept. 大剂量阿非利西普治疗的疗效及手术技术。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-08 DOI: 10.1177/24741264251352890

Ahmad M Mansour, Luiz H Lima, Maurizio Battaglia Parodi, Antonio M B Casella, Daniel G Cherfan, J Fernando Arevalo

{"title":"Outcomes of and Surgical Technique for Treatment With High-Dose Aflibercept.","authors":"Ahmad M Mansour, Luiz H Lima, Maurizio Battaglia Parodi, Antonio M B Casella, Daniel G Cherfan, J Fernando Arevalo","doi":"10.1177/24741264251352890","DOIUrl":"10.1177/24741264251352890","url":null,"abstract":"Purpose: To describe an alternate delivery of high-dose aflibercept using previous formulations (ie, prefilled syringe, vial, or compounded). Methods: A prospective pilot study was performed to analyze the short-term safety and visual gain (expressed in logMAR), including increase in intraocular pressure (IOP), resulting from a modified regimen consisting of 0.18 mL paracentesis followed by an intravitreal injection of 0.18 mL aflibercept (prefilled syringe), 0.20 mL aflibercept (vial), or 0.22 mL ziv-aflibercept (compounded). Results: The study comprised 32 eyes (16 naïve; 18 neovascular age-related macular degeneration; 8 retinal vein occlusion). Over a follow-up of 4.1 (± 3.2) months, a mean (± SD) of 1.7 (± 0.9) high-dose injections were administered. The baseline best spectacle-corrected vision was 1.35 ± 0.71 (Snellen VA) and improved to 0.68 ± 0.46 at 1 month (P < .001) and 0.57 ± 0.43 at the final follow-up (P < .001). An increase in IOP of 0.43 ± 4.26 mm Hg was seen 1 minute after injection (P = .58). In 2 eyes (6.3%), reflux as a tiny bleb was noted. Conclusions: When high-dose aflibercept is neither available nor affordable, a patient's readily accessible and cost-effective regimen of aflibercept will allow an exact delivery of high-dose aflibercept, combining minimal drug reflux, minimal immediate increase in IOP, and potential clinical efficacy in the short term.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251352890"},"PeriodicalIF":0.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fulfilling a Sense of Purpose in Medicine. 在医学上实现目标感。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-07 eCollection Date: 2025-07-01 DOI: 10.1177/24741264251352910

Timothy G Murray

引用次数: 0

2025 JVRD Contributor Awards. 2025年JVRD贡献者奖。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-07 eCollection Date: 2025-07-01 DOI: 10.1177/24741264251350192

引用次数: 0

Incidence and Impact of Outer Retinal Folds After Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment Repair. 玻璃体切割修复原发性孔源性视网膜脱离后外视网膜褶皱的发生率及影响。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-07-06 DOI: 10.1177/24741264251350023

Emily A Eton, Warren W Pan, Cagri G Besirli, David N Zacks, Thomas J Wubben

{"title":"Incidence and Impact of Outer Retinal Folds After Pars Plana Vitrectomy for Primary Rhegmatogenous Retinal Detachment Repair.","authors":"Emily A Eton, Warren W Pan, Cagri G Besirli, David N Zacks, Thomas J Wubben","doi":"10.1177/24741264251350023","DOIUrl":"10.1177/24741264251350023","url":null,"abstract":"Purpose: To determine the incidence, risk factors, and visual impact of outer retinal fold formation after pars plana vitrectomy (PPV) for macula-involving rhegmatogenous retinal detachment (RRD).Methods: A retrospective cohort study was performed of patients who had PPV with or without scleral buckling between 2011 and 2021 at a single tertiary referral center. Inclusion criteria were macular optical coherence tomography (OCT) performed within 6 weeks of PPV. Eyes with silicone oil tamponade or redetachment within 12 weeks of repair were excluded. Demographics, ocular characteristics, surgical technique, visual acuity (VA), and OCT data were analyzed.Results: This study included 154 eyes. Outer retinal folds developed in 19.2% of eyes that had OCT within 6 weeks of PPV. The mean time to resolution of an outer retinal fold was 131.9 days. Although eyes with outer retinal folds had worse preoperative vision, there was no difference in the final VA between the groups (preoperative: 20/1099 vs 20/230; P = .003) (12 months postoperative: 20/49 vs 20/46; P = .73). There was a trend toward more superior RRD in patients with outer retinal folds (P = .10).Conclusions: In this study, the incidence of outer retinal folds after PPV for macula-involving RRDs was lower than previously reported. Outer retinal folds that developed soon after surgery resolved quickly, and their presence or absence was not associated with the final VA.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251350023"},"PeriodicalIF":0.5,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144591580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy. 玻璃体切割术后硅油相关性黄斑囊样水肿的发生率及危险因素分析。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-06-26 DOI: 10.1177/24741264251345845

Jeffrey Liu, William Wirostko, Baseer Ahmad

{"title":"Incidence of and Risk Factors for Silicone Oil-Associated Cystoid Macular Edema After Pars Plana Vitrectomy.","authors":"Jeffrey Liu, William Wirostko, Baseer Ahmad","doi":"10.1177/24741264251345845","DOIUrl":"10.1177/24741264251345845","url":null,"abstract":"Purpose: To observe the incidence of and risk factors for cystoid macular edema (CME) after silicone oil (SO) implantation after pars plana vitrectomy (PPV) for retinal detachment (RD) repair. Methods: This retrospective analysis used the TriNetX database to identify patients who received SO tamponade after PPV for RD between March 2014 and March 2023. The onset and regression of CME were identified using spectral-domain optical coherence tomography. The demographics, intraoperative parameters, and postoperative disease course of patients with and patients without CME were compared using χ2 tests, Student t tests, and logistic regression models. Results: Twenty (25.3%) of 79 eyes developed CME after intraocular insertion of SO. The use of 1000 cs SO (n = 50) vs 5000 cs SO (n = 29) was significantly associated with CME onset (odds ratio, 4.46; P < .05). The mean (± SD) SO tamponade duration was 199.0 ± 125.5 days. The mean time from SO implantation to detection of CME was 82.6 ± 57.9 days. Disease regression occurred in 15 (75.0%) of the 20 eyes with CME and was recorded a mean of 218.2 ± 256.2 days after SO removal. Compared with untreated groups, the frequency of CME regression was not influenced by the administration of sub-Tenon triamcinolone acetonide (75.0% vs 75.0%; P = 1.00), prednisolone acetate eyedrops (75.0% vs 75.0%; P = 1.00), or ketorolac eyedrops (71.4% vs 76.9%; P = .79). Conclusions: The viscosity of the SO used for vitreous tamponade in RD repair may play a role in the development of CME, with lighter grade oil increasing the risk for disease. Furthermore, SO removal alone potentially leads to a prominent reduction in CME in most cases.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251345845"},"PeriodicalIF":0.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Cost Analysis of Initial Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Performed in the Operating Room vs the Clinic. 术前全视网膜光凝治疗增殖性糖尿病视网膜病变的长期成本分析。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-06-13 DOI: 10.1177/24741264251346822

Sean C Drummond, Brenton T Bicknell, Jack E Feist, Jason N Crosson, Richard M Feist

{"title":"Long-Term Cost Analysis of Initial Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Performed in the Operating Room vs the Clinic.","authors":"Sean C Drummond, Brenton T Bicknell, Jack E Feist, Jason N Crosson, Richard M Feist","doi":"10.1177/24741264251346822","DOIUrl":"10.1177/24741264251346822","url":null,"abstract":"Purpose: To evaluate a treatment-naïve cohort of patients with proliferative diabetic retinopathy (PDR) and assess the costs of panretinal photocoagulation (PRP) initially performed in the operating room or the clinic, incorporating the cost of the additional follow-up procedures required for each treatment group. Methods: A retrospective review was performed of patients with PDR initially treated with PRP in the operating room or the clinic. Cost data were derived from Current Procedural Terminology codes, and estimated mean facility costs were provided. For each cohort, negative binomial regressions were used to compare counts of subsequent interventions, and visual acuity (VA) outcomes and dollars per patient-treatment year were compared with paired t tests. Results: Eighty-two eyes of 53 patients met the inclusion criteria. The operating room cohort included 56 eyes of 38 patients, while the clinic cohort included 26 eyes of 16 patients. Patients had a minimum follow-up of more than 3 years. The operating room cohort required fewer subsequent PRP treatments (mean, 1.0 vs 2.1; P < .05) and surgeries (mean, 0.3 vs 0.7; P < .05) than the clinic cohort. The mean best-corrected VA (BCVA) after treatment was significantly better in the operating room cohort (0.30 ± 0.40 logMAR; Snellen equivalent, 20/39.9) than the clinic cohort (0.75 ± 0.81 logMAR; Snellen equivalent, 20/112.5) (P < .05). The cost per patient-treatment year was similar between the cohorts (operating room, $5,886.79; clinic, $5,657.50) (P = .75). Conclusions: PRP initially administered in the operating room was equal in cost to clinic administration and required fewer subsequent PRP sessions and surgical treatments. In addition, there was a significant improvement in the final BCVA.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251346822"},"PeriodicalIF":0.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Performance and Outcomes of a 20 000 Cuts-per-Minute, 25-Gauge, Beveled-Tip Vitrectomy Probe. 25号斜尖玻璃体切割探头每分钟切割次数20000刀的临床表现和效果。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2025-06-12 DOI: 10.1177/24741264251338871

Harvey S Uy, Jose Carlo M Artiaga, Katrina Beatriz M Lim, Pik Sha Chan, Jordan T Famadico

{"title":"Clinical Performance and Outcomes of a 20 000 Cuts-per-Minute, 25-Gauge, Beveled-Tip Vitrectomy Probe.","authors":"Harvey S Uy, Jose Carlo M Artiaga, Katrina Beatriz M Lim, Pik Sha Chan, Jordan T Famadico","doi":"10.1177/24741264251338871","DOIUrl":"10.1177/24741264251338871","url":null,"abstract":"Purpose: To report the clinical outcomes and instrument performance of a 25-gauge, 20 000 cuts-per-minute (cpm), beveled-tip vitrectomy probe system. Methods: This prospective consecutive case series comprised eyes having primary pars plana vitrectomy (PPV) using a 20 000 cpm vitrectomy probe system (20 000 cpm group). The main outcome measures were the rate of success, operative times, number of steps, 3-month distance-corrected visual acuity (DCVA), ancillary instruments use, and adverse events (AEs). A comparative analysis with the results of a previously published series of eyes that had PPV with a 10 000 cpm, beveled-tip vitrectomy system (10 000 cpm group) was performed. Results: The study included 55 eyes. The surgical objectives were attained in all eyes. The mean logMAR DCVA improved from 0.96 preoperatively to 0.35 postoperatively (at 3 months) (P < .0001). The mean (±SD) total operative time, core vitrectomy time, shave vitrectomy time, and total vitrectomy time was 1964.27 ± 846.92 seconds, 174.87 ± 116.23 seconds, 478.41 ± 387.30 seconds, and 655.60 ± 397.53 seconds, respectively. The mean number of surgical steps was 4.05 ± 1.06 and of ancillary instrument exchanges, 3.23 ± 1.89. The mean postoperative day 1 pain score was 0.16 ± 0.46. Two eyes had elevated intraocular pressure postoperatively and 1 eye had hypotony. There were fewer ancillary instrument exchanges (P < .001) and fewer AEs (P = .044) in the 20 000 cpm group than in the 10 000 cpm group. Conclusions: Both the 20 000 and 10 000 systems are effective and safe for the treatment of various vitreoretinal indications. The potential advantages of the 20 000 system include reduced use of ancillary instrumentation and lower AE rates.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251338871"},"PeriodicalIF":0.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0